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The human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) has evolved to limit its overall immunogenicity by extensive
glycosylation. Only a few studies dealing with glycosylation sites have taken into account available 3D data in a global approach. We
compared primary env sequences from patients with acute HIV-1 infection. Conserved N-glycosylation sites were placed on the gp120-3D
model. Based on vicinity, we defined glycosylation clusters. According to these clusters, we engineered plasmids encoding deglycosylated
gp160 mutants. We also constructed mutants corresponding to nonclustered glycans or to the full deglycosylation of the V1 or V2 loop. After
in vitro expression, mutants were tested for functionality. We also compared the inhibition of pseudotyped particles infection by human-
neutralizing sera. Generally, clustered and nonclustered mutants were affected similarly. Silencing of more than one glycan had deleterious
effects, independently of the type of sugar removed. However, some mutants were moderately affected by glycans removal suggesting a
distinct role for these N-glycans. Additionally, compared to the wild-type pseudovirus, two of these mutants were neutralized at higher sera
dilutions strengthening the importance of the location of specific N-glycans in limiting the neutralizing response. These results could guide
the selection of env mutants with the fewest antigenic and functional alterations but with enhanced neutralization sensitivity.
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The envelope glycoprotein (Env) of human immunode-
ficiency virus type 1 (HIV-1) promotes binding of virus to
target cells through CD4/chemokine receptors complex and
triggers events leading to fusion between viral and cellular
membranes.
During and after translation, the envelope precursor
gp160 folds in endoplasmic reticulum and acquires the
ability to oligomerize before being exported to the Golgi
apparatus. In the Golgi, gp160 is proteolytically cleaved to
create two noncovalently associated subunits, the gp120
(surface protein) and gp41 (transmembrane protein). The
gp120/gp41 association is labile and may dissociate (or
‘‘shed’’) spontaneously (McKeating et al., 1991). The0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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different strains and highly variable surface-exposed loops.
Gp160 (about 850 residues) contains about 28 sites for
N-linked carbohydrates attachment. Nearly 50% of the
gp120 mass is due to carbohydrate residues and a broad
variety of both high-mannose and complex-type have been
identified (Leonard et al., 1990; Zhu et al., 2000). Such
extensive glycosylation is very unusual regarding to the
envelope glycoproteins of others viruses. As a comparison,
the F and H glycoproteins of measles virus have, respec-
tively, 3 and 5 glycosylation sites for 550 and 617 residues
(Cattaneo and Rose, 1993). Sugars play an important role in
structural folding of nascent proteins in endoplasmic retic-
ulum, in precursor cleavage in the early Golgi apparatus,
and consequently modulate the biological properties and the
infectivity of the virus (Benjouad et al., 1992; Fischer et al.,
1996). Nevertheless, N-glycans appear to be dispensable for
maintaining gp120 native structure once formed (Fennie and
Lasky, 1989; Li et al., 1993). Glycosylation is also a mean
of diversifying proteins without recourse of the genome and
a growing body of evidence demonstrates that it modulates
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patients or in experimentally infected animals, acting like a
shield (Cheng-Mayer et al., 1999; Schonning et al., 1998;
Wei et al., 2003a, 2003b).
The envelope glycoprotein is the target of virus-neutral-
izing antibodies; however, it does not elicit efficient neu-
tralizing response in infected people. The high number of N-
glycans could partially explain why broad neutralizing
antibodies directed against envelope glycoprotein have not
been frequently identified.
Several reports have described individual substitutions of
N-glycosylation sites located on domains implied in the
resistance to antibody-mediated neutralization. These
domains include V1/V2 or V3 loops that mask CD4 binding
sites or epitopes induced after binding of the CD4 (CD4-
induced epitopes). Except for the gp41 moiety and for the
gp120 variable loops, few systematic has been made,
especially regarding the spatial location of N-glycans (John-
son et al., 2001; Desrosiers et al., 1998; Hemming et al.,
1996; Lee et al., 1992; Ogert et al., 2001). In addition,
studies were mainly conducted on SIV or HIV-1 T-cell line-
adapted viruses (TCLA). It is now well accepted that this
type of virus is antigenically faraway from primary clinical
isolates and typically more sensitive to antibodies neutral-
ization (Moore et al., 1995).
In order to be as close as possible to the virus that has
founded the infection, we chose to base our study on gp120
sequences from HIV-1 acute infection primary isolates. It
was recently postulated that the ‘‘glycan shield’’ was evolv-
ing during the course of infection in the face of a changing
antibody repertoire (Wei et al., 2003a). We made the
hypothesis that at the time of acute infection, the well-
conserved glycosylation sites would be located in specific
regions at the surface of the protein and serve to protect
against humoral immune response gp120 epitopes critical
for HIV-1 transmission. According to the 3D-model data,
we mutated potential glycosylation sites to remove sugars
on these different regions.
In this approach, the major obstacle was to increase
immunogenicity without altering the oligomeric gp120:
we monitored the effects on Env processing and function;
we also tested the neutralizing activity of human sera on
pseudotyped particles harboring mutated envelopes. These
data could be useful for rationalizing the design of new Env
immunogens that would induce a strong broad range anti-
body response against the HIV-1.Results
Rational of deglycosylation constructs
To identify conserved N-linked glycosylation sites of
HIV-1 gp120, 14 primary env sequences obtained during
acute infection and before seroconversion were aligned
(Fig. 1). These sequences were generated from patientsinfected sexually (eight homosexuals, six heterosexuals).
The sequence alignment revealed the presence of 10 well-
conserved N-glycosylation sites (defined by the NX{-P}T/
S sequon), spread all over the gp120 amino acids sequen-
ces (N44, N88, N109, N123, N148, N201, N243, N253,
N289, and N301/307). The N185 site was present in all
sequences from homosexually transmitted isolates. Two
other potential sites (N136, N142) were conserved among
env sequences from heterosexually transmitted isolates. The
133 env sequence retained for mutants construction has
been isolated from a patient contaminated by the homo-
sexual route; consequently, the N185 site was included in
the study. Due to the systematic presence of at least one
sugar at the close positions N231/N237, the N231 site was
also included. The N136/N142 sites, as well as the N81
site, were not considered as they were absent from the 133
env sequence. Due to their proximity on 133 sequence, the
N-glycan sites N180/N185 (as N201/N208) are removed
simultaneously.
To analyze the 3D distribution of the selected N-glyco-
sylation sites on the 133 sequence, we used the gp120
model based on the X-ray crystallography data (Kwong et
al., 1998). Each potential site was highlighted on the 3D
model. The selected sites were arbitrarily grouped into three
nonoverlapping ‘‘regions’’ (or ‘‘cluster’’) based both on the
proximity of each site with the others (Fig. 2). The size of
each cluster was roughly delimited by a 20 A˚ circular area,
considered as the typical antibody footprint (Pantophlet et
al., 2003). The first region (colored in red; A region; Fig.
2A), constituted by sites N44, N231, and N243, was located
approximately on the bridging sheet, which is implied in
receptor and coreceptor binding. The second region, pre-
sented in blue (B region; Fig. 2B), grouped the positions
N148, N180/N185, N201/N208. This cluster was separated
from the first one by several residues (Q227, L262, and
P279) critical for coreceptor binding (Rizzuto et al., 1998).
Two out of four glycosylation sites in the B cluster (N180
and N185) also belonged to the 2G12 neutralization epitope
(Scanlan et al., 2002). The third region (C region; Fig. 2C),
represented in yellow (N109, N253 and N289), was located
on the gp120 silent face, which is well exposed at the
surface of the envelope oligomer but does not induce
antibodies. Among the remaining positions, the N88 and
N301/307 sites were not retained for our study, as they
belonged to the inner domain of the gp120 that faces up the
gp41 moiety. This domain is poorly accessible in Env
oligomers and does not induce neutralizing antibodies. As
the N123 site (colored in green) remained alone, it was
grouped with sites in the neighborhood at positions N109
and N289 (C cluster) or N148 (B cluster) and defined the
‘‘D’’ mutants. All of four were roughly located near the
base of the V3 loop. These mutants were considered as a
separate group.
The clusters definition was validated by checking con-
served N-glycans location on 3D model for the 13 others
primary gp120 sequences (data not shown).
Fig. 1. Positions of the potential glycosylation sites on 14 gp120 primary sequences from patients with HIV-1 acute infection. The amino acids numbering of N
mutations corresponds to the HIV-1HXB2 gp120 sequence deleted for a part of C1 and C5 regions and for the V1V2 loop as described by Kwong et al. (1998).
The code number of the patients and the contamination route, homosexual (HM) or heterosexual (HT), identify each sequence. The position of the missing
V1V2 loop is indicated by a triangle.
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engineered (Table 1); in a series of mutants, all the N-
glycan attachment sites belonging to the same region were
removed (g4A, g5B/g6B, g5C, respectively, for the A, B,
and C clusters). As several intermediates were generated
for this purpose, they were also included in the study
(g1A–g3A, g1B–g4B, g1C–g4C). In parallel, the effects
induced by two (g1), three (g2), or four mutations (g3),
but not located in the same region, were evaluated (Fig.
2D). The deglycosylation of the V1 loop (g4) or the V2
loop (g5) are modifications that improve the capacity of
the Env protein to induce neutralizing antibodies or its
sensitivity to neutralizing sera (Reitter and Desrosiers,1998; Quinones-Kochs et al., 2002). We made these
mutations on the 133 env sequence to complete our study
because the crystallized core-gp120 is devoid of the V1/
V2 loops. For all the constructs, the potential N-glycosyl-
ation sites were removed by replacing the asparagine
residue (N) in the NX{-P}T/S sequons by a glutamine
residue. Glutamine was chosen because of its structural
similarity with asparagine differing by only a single
methylene group. In addition, a minimum of two nucleo-
tides changes are necessary to revert to the original
asparagine codon. All the constructs were checked by
sequencing both strands to exclude mutations induced by
PCR during mutagenesis.
Fig. 2. (A–C) Positions of the mutated N-glycosylation sites on the 133 gp120 sequence according to the gp120 crystallized model viewed on three different
angles. Each asparagine from the canonical motif NX{-P}T/S is highlighted by different colors according to its respective region. The amino acid numbering
corresponds to the variable loops deleted envelope sequence. The missing V1/V2 structure is schematized by a gray oval. The 20 A˚ bar represents
approximately the size of an antibody footprint. (D) Positions of asparagine residues according to the nonclustered mutants definition viewed on two different
angles.
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gp120 shedding
To determine the effect of cluster deglycosylation on
envelope processing and particularly on cleavage, 293T
cells were transfected and both the lysates and the cell
culture supernatants were analyzed by an anti-gp120 im-
munoblot (Fig. 3). Luminescence scanning was used to
detect the immunoreactive bands on immunoblots on cell
lysates. As the Rev protein is necessary to Env synthesis,
we checked that it was present at the same level in all
lysates (data not shown). All constructs were expressed at
a comparable order of magnitude (Fig. 3). The mobility of
the gp160 and gp120 gene products expressed from g1A–
g2A, g1B, g1C–g2C, and g1D constructs appeared to be
close to the one of the wild-type proteins. For these
mutants, only one or two glycosylation sites were re-
moved. The gp160 of all others mutants migrated slightly
faster than wild-type gp160. This result confirmed the loss
of glycans caused by mutagenesis; the glycosylation of one
N-glycan attachment site is predicted to contribute approx-
imately 2–3 kDa to the apparent molecular mass of a
protein.
For the mutants with one N-glycan removed (i.e., g1A,
g2A, g1B, g1C, g1D, but not g2C), gp120 was detected incell lysates. Gp120 was also detected for g3C (two muta-
tions), g4 (three mutations), and g3B (four mutations). For
g2B, g4B, g6B, g2C, g4C, g5C, and g2D, the gp120 was
exclusively detected in the culture supernatants: a particu-
larly important shedding caused absence of detectable
gp120 in cell lysates. An Env bearing one unique mutation
at N109 or N148 was affected similarly indicating the
leading role of these mutations in gp120/gp41 dissociation
(cf. g2C; data not shown for N148). For the remaining
mutants, no gp120 was detected both in the lysate and the
supernatant; for these mutants, the gp160 cleavage was
severely impaired. The removal of the three potential sites
present on the V1 loop (g4) had no effect on the cleavage
rate compared to the native protein. Cleavage on nonclus-
tered mutants was affected in the same way as the clustered
mutants. Additionally, the effects were apparently indepen-
dent of the nature of the removed sugars (complex or high-
mannose type, cf. Table 1).
Influence of N-glycans removal on cell membrane
presentation and incorporation in pseudovirion
Cell-to-cell fusion assays on GHOST-CCR5 cells were
performed (Fig. 4A). This type of experiment was carried
out with 293T cells expressing the different mutants. The
Table 1
Glycosylation status of the engineered mutants
Region Mutants Positions of
mutated N-glycan
attachment sites
gp120 regions
mutated
N-glycans
removed
WT no-mutation
wild type
– –
anti no-mutation
insert in reverse
orientation
– –
(A) Red g1A 44 C2 (V1V2 stem) 1C
g2A 243 V4 1C
g3A 243–231 V4–V4 1C1M
g4A 44–231–243 C2–V4–V4 2C1M
(B) Blue g1B 180/185 C3 2M
g2B 180/185–148 C3–V3 1C2M
g3B 180/185–201/208 C3–C3 1C2M1U
g4B 180/185–148–
201/208
C3–V3–C3 1C3M1U
g5B 180/185–201/
208–231
C3–C3–V4 1C3M1U
g6B 180/185–148–
201/208–243
C3–V3–C3–V4 2C3M1U
(C)Yellow g1C 289 C4 1M
g2C 109 C2 1H
g3C 289–253 C4–V4 1M1C
g4C 289–109 C4–C2 1M1H
g5C 289–253–109 C4–V4–C2 1M1C1H
(D) Green g1D 123 C2 1C
g2D 123–148 C2–V3 2C
g3D 289–109–123 C4–C2–C2 1C1M1H
Misc. g1 289–123 C4–C2 1C1M
g2 289–123–243 C4–C2–V4 2C1M
g3 289–123–243–
180/185
C4–C2–V4–C3 2C3M
g4 V1 deglycosylated V1 2C1U
g5 V2 deglycosylated V2 2C
For each mutant, location, number, and nature of sugar removed are
indicated. C: complex-type sugar, M: high-mannose type sugar, H: hybrid
type sugar, and U: unknown type sugar. The numbering of N-glycan
positions is according to Fig. 1.
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the Env glycoprotein and on its exportation to the cellular
membrane. The number of syncytia decreased with the
number of mutations, correlating with the gp160 cleavage
impairment and edifice instability as described in previous
section. Compared to the wild-type Env, the loss of one orFig. 3. gp160 and gp120 immunoblots after 293T cells transfection. Detection was
weight standard of migration (kDa). To normalize sample loading, an anti-h-actin
supernatant.sometimes two glycosylation sites (g3A, g3C, and g1) had
little impact on syncytia formation. This biological assay is
more sensitive than an immunoblot, and we noticed a fusion
capacity even for some mutants for which no gp120 was
detected on blot (i.e., g3A, g1 or g5, and in a lesser extent,
g5B and g2). No fusion was observed for g4A, g5C, g3D
(three mutations), g3 (five mutations), and g6B (6 muta-
tions). For g6B and g5C, the gp120 was detected by
Western blot in supernatant but not in cell lysate, suggesting
that the protein was exported to the cell surface and the
gp120 heavily shed. Apparently, the remaining gp120/gp41
was not able to induce cell-to-cell fusion. Unexpectedly, the
mutants g4 and g3B with three and four mutations, respec-
tively, had a fusion capacity comparable to the wt. Glyco-
sylations located near or within the V1/V2 or the V3
variable loops could play an important role in coreceptor
usage and CD4 dependence (Kolchinsky et al., 2001;
Pollakis et al., 2001). We tested fusion on CD4+–CXCR4+
cells and CD4–CCR5+ cells (GHOST-CXCR4 and HOS-
CCR5, respectively). In our hands, no mutant proteins
induced fusion on these cells (data not shown).
The exportation of Env to the cell membrane does not
presume its incorporation into virions. In order to know if
the mutant proteins could be incorporated with preserved
functionality into viral particles, we generated pseudotyped
particles with the different mutants and tested the capacity
of these pseudoviruses to infect several GHOST cell lines
(Fig. 4B). The envelopes for which no or few cell-to-cell
fusion occurred showed no infection, neither on GHOST-
CCR5 nor on GHOST-CXCR4. The results for g4B, g2C,
g4C, g2D, and g5 were more ambiguous because no
infection was noticed although cell-to-cell fusion assay gave
syncytia. For mutants g3A and g1, the level of infection was
unexpectedly weak considering their important fusion ca-
pacity. These results were reproducible and indicated a
difference between Env presented to the cell surface and
Env incorporated in enveloped pseudovirions.
Immunoblots carried out on pseudoparticles after sedi-
mentation by ultracentrifugation on sucrose cushion con-
firmed the previous results (Fig. 4C); the gp120 and the
gp41 were detected only on pseudoviruses that infected
indicator cells the most efficiently. For g2C and g4C, the
gp41, but not the gp120, was detected. 
made with a polyclonal antiserum directed against gp120. MW: molecular
monoclonal antibody was used (A; bottom). L: cell lysates; S: cell culture
Fig. 4. Env exportation to cell membrane, incorporation in pseudoparticles, and infectivity. (A) Cell-to-cell fusion assay. 293T cells expressing the different
mutant genes were cocultivated with GHOST-CCR5 cells. ( ): fusion as on negative control, that is, < 5 syncytia/10 fields; (++): fusion equivalent to wild
type, that is, 60–100 syncytia/10 fields; (+) and (+/ ): intermediate levels of fusion, that is, 20–50 and 5–15 syncytia/10 fields, respectively. Results
correspond to the average of two independent experiments conducted in duplicate. (B) GHOST cells infections by pseudoparticles. Pseudotyped particles were
incubated with GHOST-CCR5 cells and subsequent luminescence was read in cell lysates. Results correspond to the average of two experiments made in
triplicate. (C) Purified pseudoparticles immunoblotted with a polyclonal antibody directed against gp120 (top) and gp41(bottom). Samples were normalized
after p24 quantification.
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The ability of Env to bind CD4 is an important feature
that could be used to give information about the general
conformation and the functionality of the mutants. Antigen-
capture ELISAs were carried out on both cell lysates and
culture supernatants of transfected 293T cells (Fig. 5). The
samples were the same with those used for the Western
blots. These ELISA were revealed with soluble CD4
(sCD4)/anti-CD4 antibody. Mutants with important alter-
ations such as g4A, g5B, g3D, or g2–g3 have not been
taken into account. Compared with the gp120 detected in
lysates, the signal in culture supernatants reflected both the
cleavage efficiency and the instability of the gp120–gp41
association. These results confirmed Western blot experi-
ments (Fig. 3) but with more sensitivity. Taken as a whole,
the removal of several glycosylation sites had little impact
on sCD4 binding. However, for g6B-6 mutations (and in a
lesser extent, for g3B-4 mutations), the decrease in super-
natant signal was probably attributable to antigenicity
disturbance because the relative amount of gp120 detected
on blot was equivalent to gp120 detected for g1B or g4B
(Fig. 3). When ELISA with serial dilutions of sCD4 were
performed, some mutants with one mutation had a relative
affinity better than the wild-type protein; the sCD4 half-
maximum binding was 0.05 Ag/ml for mutants g2A, g1B,
and g1C, and 0.15 Ag/ml for wild-type (data not shown).
Removal of N243, N180/185, or N289 improved sCD4
binding.In order to compare the respective effects of mutations on
both sCD4 binding and overall antigenicity, another ELISA
was carried out with the autologous serum from patient
#133 (Fig. 5). The results were comparable to those
obtained on the sCD4-ELISA. Mutations had little impact
on sera recognition compared to native protein. No signif-
icant difference was noticed between clustered and non-
clustered mutants. Surprisingly, although the g2C, g4C, g5C
mutants were relatively well recognized by serum, no signal
was monitored for sCD4 binding probably because muta-
tions affected mainly CD4 binding site. For g1 and g3A,
despite the lack of gp120 detected in Western blot (Fig. 3),
we found a little but significant signal in supernatant and
lysate indicating that these mutants were cleaved and
exportated.
Neutralizing activity against pseudoparticles bearing Env
glycomutants
To ascertain the influence of the glycosylation on sensi-
tivity to antibody-mediated neutralization, four sera speci-
men from HIV-1-infected patients were tested for their
ability to neutralize infectious pseudotyped particles in an
in vitro neutralization assay using GHOST CD4+–CCR5+
cell line. One serum was taken from patient #133 two years
after the acute phase, and the three others corresponded to
titrated neutralizing sera from a previous study (Burrer et al.,
2001). These sera had a measurable neutralizing activity
against several primary isolates. The results are displayed in
Fig. 5. Accessibility of the CD4 binding site. ELISAwas carried out both on lysates (A) and culture supernatants (B) from transient expression in 293T cells.
Detection was made with sCD4/anti-CD4 antibody and with the autologous serum from patient #133. Results correspond to the average of two independent
experiments conducted in duplicate. The threshold (horizontal line) was defined as 3 times the background read on the negative samples.
F. Reynard et al. / Virology 324 (2004) 90–10296Table 2 as 50% inhibitory titer (IT50). The results were
compared to those obtained for the parental env gene. The
four neutralizing sera showed a greater inhibitory titer for
two glycomutants than for the wild type; CCR5-mediatedTable 2
Neutralization of pseudoviruses with 1:2 serial dilutions of neutralizing and
nonneutralizing human sera
Pseudovirions Neutralizing sera
1 2 3 4 5
g2A 570 180 60 1300 20
g1B 820 150 60 1300 80
g3B 1350 1120 250 1600 80
g1C 510 120 45 400 80
g3C 490 150 25 800 50
g1D 640 160 250 1300 80
g1 1090 300 180 700 10
g4 2500 2000 800 1600 30
wt 720 210 45 750 80
Values correspond to serum dilution required to yield z 50% reduction of
infection by 8.104–105 RLU-equivalent promoting infection of pseudo-
typed viruses. Results correspond to the average of two experiments
performed in triplicate. The column #1 corresponds to the autologous serum
from patient #133. The columns #2–4 correspond to titrated HIV-1 human-
neutralizing sera. The column #5 corresponds to an HIV-1 negative serum.infection was neutralized more efficiently (Table 2, columns
#1 to #4). These two mutants corresponded to the complete
deglycosylation of the V1-loop (g4) and to four mutations in
the blue cluster (g3B). The results displayed in the previous
section showed that these mutants were structurally and
functionally barely affected despite a large number of N-
glycans removed. For g1D (one mutation in D cluster) and
for g1 (two mutations but not in a cluster), a notable
neutralization effect for some sera was noticed. Only a
weak neutralizing activity was detected for HIV-1 negative
serum (10 < IT50 < 80; column #5).Discussion
In the present report, we aimed at the determination of
the biological properties of Env glycomutants designed
from the available 3D structure. We used HIV-1 acute
infection primary isolates (PHI) to work with env sequences
from the early stage of the disease, as close as possible to
the transmission event. At this stage, viruses are still
homogenous in sequence (Delwart et al., 2002). Moreover,
the glycan shield could evolve during the course of infection
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judicious to focus on primary sequences isolated early after
the infection. Alignment of 14 PHI gp120 allowed us to
select conserved glycosylation sites, which could be
grouped into four regions of occupancy when laid on a
3D model. We hypothesized that such a conservation and
clustering could reflect a role in shielding crucial gp120
epitopes during HIV-1 transmission. To check this hypoth-
esis, we engineered gp120 glycomutants with progressive
deglycosylation of each region. Each mutant was tested for
both its functional and antigenic properties and compared to
the wild-type protein.
The number of sequences analyzed was not sufficient to
be sure that the positions we chose as conserved are indeed
found in all HIV-1 isolates, but we can assume that these
positions are at least well conserved. Moreover, the ana-
lyzed sequences were almost exclusively from B clade
except two of them belonging to E and G clades (sequen-
ces #355AHT and #365AHT, respectively). Even if some
cohorts of acute seroconverters have been extensively
studied (Delwart et al., 2002; Freel et al., 2003; Hu et
al., 2000), they are few complete env sequences from PHI
available in HIV-1 sequences databases. A comparison
between our 14 gp120 PHI sequences and two other ones
found in databases (GeneBank accession nos. U32396 and
AF310108) showed that the N-glycan sites we selected
were actually present in these two PHI sequences (data not
shown). The repartition of the different conserved potential
glycosylation sites on the 3D model showed that N-glycans
could be located in specific regions. These regions are
virtual because of the arbitrary nature of our clusters: as the
available crystallized gp120 is partially deleted and its
association with the sCD4 and 17b Fab probably induced
conformational changes compared to gp120 alone, we
considered alternate possibilities to enlarge the definition
of each region. We chose to restrain the number of
deglycosylation to six because it had been previously
proposed that Env can tolerate around five mutations in
combination without disturbance of the infectivity (Ohgi-
moto et al., 1998; Reitter and Desrosiers, 1998).
Transient expression of the env glycomutants in the 293T
cells and subsequent Western blots analysis showed that
cleavage of the precursor gp160 into gp120 and gp41 was
affected by the number of N-glycans removed. Previous
studies have shown that removing of one N-glycan has no
impact on biosynthesis and functionality of gp160, but more
mutations (3–5) have major effects (Dirckx et al., 1990;
Fenouillet et al., 1994). In our hands, if one—or exception-
ally more mutations (g3B, g3C, and g4)—had generally
little impact on processing, the accumulation of three to six
mutations entailed a dramatic decrease in gp160 cleavage
and gp120/gp41 cohesion. This could be explained by the
misfolding of the partially deglycosylated protein or the
inefficient trafficking from endoplasmic reticulum to trans-
Golgi, where the cleavage by cellular endoproteases occurs
(Moulard and Decroly, 2000). These results are compatiblewith previously published data (Johnson et al., 2001;
Quinones-Kochs et al., 2002; Reitter and Desrosiers,
1998). Both the number and the specific location of the
silenced N-glycans seemed to have additive effects. If some
N-glycans (especially at positions N109 and N148) play a
foreground role, others seem to be more accessory in terms
of functionality and antigenicity, notably those located on
the V1 variable loop and some in the B (e.g., N180/N185 or
N201/N208) or in the C cluster (N289, N253).
The positive results in cell-to-cell fusion assays indicated
that sufficient level of functional Env was expressed on the
cell surface. In this assay, fusion observed on GHOST-
CCR5 cells was inversely related to the number of N-
glycans removed. Previous studies have shown that all N-
glycans on V1 or V2 loops on HIV-1 primary isolate could
be mutated without affecting expression on the cell surface.
However, mutations reduced (four or five sites) or sup-
pressed (six sites) fusion activity (Quinones-Kochs et al.,
2002). The N-glycans on the V1/V2 stem and V3 loops have
often been described as playing an important role in HIV-1
strains coreceptor usage (Nakayama et al., 1998; Pollakis et
al., 2001). In our experimental conditions, no cell-to-cell
fusion was observed for the mutations N44 (V1/V2 stem)
and N148 (V3) when GHOST-CXCR4 cells were used as
indicators.
In order to characterize the effects of clustered N-glycans
mutagenesis on CD4 binding site, sCD4 binding was tested
by ELISA. It was barely affected by mutations. For some
mutants (g2C, g4C, and g5C), mutation at position N109
played an unfavorable role on sCD4 binding compared to
the results obtained on some constructs without mutation at
this position (g1C and g3C). Mutation N109 is located in
the C2 domain, 30 residues upstream the V3 loop. It has
been previously reported that N109Q substitution in HIV-1
is critical for the intracellular process of gp160, for the
ability of gp120 to bind to CD4, and for the infectivity by
reduction in the amount of gp120 incorporated in virions. It
has been proposed that such impairment could be due to
interactions disturbance between C2 and V3 regions (Willey
and Martin, 1993). Interestingly, the glycosylation site at
N109 is exceptionally well conserved in all Env primate
retroviruses (Kwong et al., 1998). Although g2C and g4C
were dramatically affected for sCD4 binding, they induced
syncytia formation in cell-to-cell fusion experiment on
GHOST CD4+–CCR5+. It could be tempting to conclude
that these mutants have acquired CD4 independence; how-
ever, cell-to-cell fusion assay on HOS CD4–CCR5+ did
not show any syncytia.
Results obtained with pseudovirions indicated that the
incorporation efficiency depends on the number of glycans
removed. The correct processing of the precursor gp160
seems required for Env incorporation into viral particles
(Dubay et al., 1995; McCune et al., 1988). The uncleaved
form of the HIV-1LAI Env is highly presented at the cell
surface but particles following budding from the cell surface
are devoid of gp160 precursor (Moulard et al., 1999); other
F. Reynard et al. / Virology 324 (2004) 90–10298data suggested that the entire gp120 with an adequate
conformation is required for Env complex incorporation
into virions (Li and Perez, 1997).
The mutants g3A and g1, despite cleavage alteration,
induced a high number of syncytia and promoted infec-
tious pseudoparticles formation. These results suggested
that the few gp160 that is correctly processed at the cell
membrane kept their functionality and could be incorpo-
rated into virions. The differences observed between fusion
assay and infectivity assay for mutants g2C and g4C could
be also imputed to the low density of functional Env found
on cell membranes, which has repercussions on virion
envelope composition. Detection of gp41, but not gp120,
on pseudovirions g2C and g4C provided the confirmation
of N109 influence upon Env edifice stability; the not yet
shedded gp120/gp41 edifices present at the cell surface
(which induced fusion in cell-to-cell fusion assay) would
be incorporated into pseudovirions, but once in pseudovi-
rions, the gp120 would shed. The cell-to-cell fusion assay
is a very sensitive test for monitoring Env functionality
because in theory, a single functional Env oligomer must
be sufficient to promote membranes fusion on susceptible
cells and therefore to lead to the formation of a detectable
fusion event. This could explain why some mutants
showed cell fusion although the gp120 could not be
detected by immunoblot.
With one unique mutation at position N44, the mutant
g1Awas correctly processed. Unexpectedly, a weak level of
cell-to-cell fusion and infection was observed. Previous
studies suggested that the glycan located at N44 influences
the spacial location of the V1/V2 loop of HIV-1ADA
glycoprotein and consequently modulates the accessibility
of the coreceptor binding site (Kolchinsky et al., 2001). We
propose that for g1A, the mutation relocates V1/V2 the
same way but resulting in a reduced accessibility of the
CCR5 binding site.
Early studies showed that the acquisition or the removal
of glycans in variable loops of HIV-1 or SIV modify the
sensitivity of these viruses to neutralization (Bolmstedt et
al., 1996; Chackerian et al., 1997; Matsushita et al., 1988).
In our hands, the most remarkable results were obtained on
mutants devoid of three N-glycans in V1 or 4 N-glycans in
C3 (g4 and g3B, respectively). It has been suggested that the
density of the envelope spikes on the surface of virions can
influence relative sensitivity to antibody-mediated neutrali-
zation. If mutations result in a decrease in spikes incorpo-
ration or in a high level of spontaneous shedding, then the
increased neutralization sensitivity could reflect a reduction
in the number of antibodies required to inhibit mutant
virions (Burton et al., 2000). However, immunoblots made
on pseudotyped particles showed that neutralization sensi-
tivity was independent on the intensity of the gp120 signal.
For V1 deglycosylation (g4, three mutations), there is
apparently a few differences comparing wt Env. However,
g4 pseudotyped particles are more sensitive to human-
neutralizing sera. The V1/V2 loop is a bulky domain thatemerges from the gp120 core; moreover, V1 loop is struc-
tured by three disulfide bridges: this particular topology
could explain why deglycosylation led to small differences
in structure and processing comparing parental glycopro-
tein. However, a complete deglycosylation of the V2 loop
(g5, 2 mutations) caused a drastic impairment for gp160
cleavage, conformation, and CD4 binding. Both structures
have complex-type sugar linked to asparagine (and an extra
glycan not yet characterized, for V1). Apparently, the
chemical nature of glycans does not explain differences
observed between the two mutants.
Thus, we can hypothesize that some sugars play an
essential role during Env biosynthesis and processing
(e.g., sugars linked at residues N109 and N148); the
silencing of these sugars entails defects on cleavage or
gp120/gp41 stability. A second type of sugar plays an
accessory role in envelope processing but probably serves
to shield protein against antibodies by evolving during the
course of the disease. The sugars removed from g3C, g4,
and g3B mutants would belong to this second type. This
hypothesis agrees with a previous study showing that N-
glycans important for infectivity were not randomly distrib-
uted on HIV-1HXB2 gp120, and consequently, the role of the
remaining N-glycans would be to evade the host immune
response (Lee et al., 1992). Interestingly, N-glycan sites
silenced on g4 and g3B are separated by few residues (less
than eight amino acids) and could be considered as redun-
dant. Moreover, the asparagine residues mutated for g3C or
g3B locate close together on 3D model. This special
topology strengthens the hypothesis of evolving and adapt-
able positions for N-glycans shield in face of the antibody
repertoire.
Recent results suggested that high-mannose residues
defining 2G12 epitope play a foreground role in DC-SIGN
or related lectins binding (Sanders et al., 2002). The 2G12
human monoclonal antibody neutralizes HIV-1 in vitro and
protects macaque in association with others antibodies in
passive immunization experiment from Simian-HIV-1
(SHIV) virus challenge (Mascola et al., 2000; Trkola et
al., 1996). The N-glycans N180–N185 from the B region
take part in 2G12 epitope. They are silenced in g3B mutant.
Thus, we can also hypothesize that in this area, the presence
of a patch of N-glycans has a critical importance on virus–
cell interactions. Consequently, antibodies directed against
this region of Env could interfere with lectins binding and
thus could allow better viruses neutralization.
The differences between the mutants and wt protein are
not the result of gross defect in expression or processing of
the envelope complex because the majority of mutants were
cleaved and exported to the cell surface. The cleavage and
the conformation disturbance are apparently independent of
clustering mutations or glycan type. However, results can be
modulated in function of the respective position of each
glycan removed on the gp120, underlining the different role
of each sugar in the Env protein characteristics. Although
our integrated approach, taking into account the 3D disper-
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demonstrate a cluster-specific role of N-glycans in Env
function and immunogenicity, it has led us to identify new
potential immunogens. If the criteria in the choice of a Env
immunogen suitable for neutralizing antibodies induction
are based on the preservation of the structure as much as
possible, but with an enhanced exposition of critical epito-
pes and correlatively enhanced neutralization, the g3B and
g4 mutants are good candidates.Materials and methods
Sequence data
Nucleotide sequences coding for the entire gp160 env
region were generated from DNA PBMC from patients
with acute HIV-1 infection. These sequences were de-
scribed in a previous study (Ataman-Onal et al., 1999).
They were named 133 AHM, 146 AHM, 153 AHM, 159
AHM, 160 AHM, 374 AHM, 384 AHM, 385 AHM
(homosexual transmission), 120 AHT, 309 AHT, 355
AHT, 365 AHT, 373 AHT, and 426 AHT (heterosexual
transmission). All sequences were aligned with CLUS-
TALW (MacVector software, Oxford Molecular Group).
The 3D model was based on the coordinates for the HIV-
CD4-17bFab antibody complex deposited in the Protein
Data Bank as entry IG9M. Molecules were drawn with
PDBwiever (Glaxo-Smithkline).
Site-directed mutagenesis
Wild-type 133 env sequence was cloned into the Xho1–
Xba1 sites of the pCI expression vector (Promega, Madison,
USA) using standard protocols. To remove potential N-
glycosylation sites, asparagine to glutamine substitutions
were carried out using the QuickChange site-directed mu-
tagenesis kit (Stratagene, La Jolla, USA). All mutant con-
structs were checked by sequencing both strands on a 377
automatic sequencer (Perkin-ABI, Boston, USA) with the
PRISM Big Dye terminator V.02 (Perkin-ABI). Plasmid
DNA was prepared using the NucleobondPC500 kit
(Macherey-Nagel, Du¨ren, Germany).
Cells transfection and pseudovirions generation
293T cells were used for transfection experiments and
were cultivated in MEM (Gibco-LifeTech, Gaithersburg,
USA) supplemented with 10% fetal calf serum, 1% nones-
sential amino acids and 1% Na-pyruvate (Gibco-LifeTech).
Cells (8.105) were cotransfected with 0.2 Ag pCI-rev and 1
Ag of the different pCI-env constructs using the Lipofect-
AMINE Kit (BRL, Rockville, USA). The env gene cloned
in reverse orientation in the same vector (pCI-anti) was used
as a negative control. Cells were harvested 24 h (for cell-to-
cell fusion assay) or 48 h later (for both immunoblots andELISA). Alternatively, pseudovirions stocks with wild-type
or env mutants were generated as previously described with
the help of the env-deficient viral reporter vector pNL43-
LucR-E- (Park et al., 1998). Supernatants containing pseu-
doviruses were harvested 48 h post-transfection and frozen
at 80 jC. The amount of virus particles was determined by
Vidas-p24 tests (bioMerieux, Marcy-l’Etoile, France).
In vitro cell-to-cell fusion assay and infectivity assay
Twenty-four hours post-transfection, 293T cells were
harvested and replated at 105 cells in a 12-well plate. The
unseeded cells were used to check gp120 expression by an
immunoblot. Cells were left to re-adhere during 6 h, then
GHOST-CD4+CCR5+,GHOST-CD4+CXCR4+, or HOS-
CD4CCR5+ cells were added (106 cells/well) and incubat-
ed during 16 h. The cells were fixed 15 min in 0.5%
glutaraldehyde, colored in May–Gru¨nwald/Giemsa stain,
and syncytia were observed with an optical microscope.
Alternatively, 106 GHOST cells were infected by pseudovi-
ruses (50 ng p24/wells). After 12 h of incubation, inoculum
was replaced by 1 ml of fresh culture media. After 72 h, the
cells were lysed and luciferase activity was measured with
the Luciferase Assay Kit (Promega) on a luminometer (TD
20/20, Turner).
Western blot
The same protocol was used for both cell lysates, culture
supernatants, and pseudoparticles pellets. Forty-height hours
post-transfection, cells were harvested, washed once with
PBS1x, lysed in TBS1x/NP40 1%, and finally cleared by
centrifugation (15000 g/10 min). The culture supernatants
were cleared of the cell debris by centrifugation (15000 g/10
min). The pseudoparticles (equivalent to 500 ng of p24) were
pelleted 3 h at 20 000 g on a 20% sucrose cushion and then
lysed by 50 Al of TBS1x/NP40 1%. The proteins were heat-
denatured in presence of h-mercaptoethanol and separated
on a 8% SDS-polyacrylamide gel. After electro-transfer, the
membrane (Hybon-P; Amersham-Pharmacia, UK) was sat-
urated in PBS1x/Tween 200.1% nonfat dry milk 3% and
incubated overnight at 4 jC with a goat anti-gp120 poly-
clonal antibody (Biogenesis ref. 5000–0557, Poole, UK; 1
Ag/ml). Alternatively, an anti-gp41 monoclonal antibody
(F240, NIH AIDS Research and Reference Reagent Pro-
gram, Rockville, USA) was used at 1 Ag/ml. After extensive
washing, the membrane was incubated for 45 min at room
temperature with peroxydase-conjugated antibodies (Jack-
son, West Grove, USA; 0.1 Ag/ml). Detection was performed
using the ECL reagent (Amersham-Pharmacia; UK). Sam-
ples were normalized by densitometry on a Typhoon 8600
reader (Amersham-Pharmacia, UK) based on the detection of
the Rev and Actin proteins on immunoblots with monoclonal
antibodies against Rev (1F6D1B7; bioMe´rieux, Marcy-
L’Etoile, France) and against human actin (A4700; Sigma-
Aldrich, St. Louis, USA).
rology 324 (2004) 90–102ELISA
Env ELISA-capture was carried out on cell-culture
supernatants and cell lysates processed as described above.
The D7324 polyclonal antibody (Aalto, Dublin, Ireland)
was used as capture antibody as previously described
(Brand et al., 2000). After normalization of total protein
concentration with the BCA protein assay kit (Pierce,
Rockford, USA), cell lysates were diluted at 1:10 in
TBS/NP40 1%/New-Born Calf Serum 2%. For detection,
the autologous HIV + serum from #133 patient (B clade;
hoˆpital de la Croix-Rousse; Lyon, France) was used at 1/
100 dilution. Alternatively, soluble CD4 (sCD4, NIH AIDS
Research and Reference Reagent Program) was used at a
final concentration of 0.5 Ag/ml. The soluble CD4 was
detected with the BAF 379 monoclonal antibody (R&D,
Abington, UK) directed against its V4 loop. Each result
corresponded to the mean of two independent experiments
made in duplicate.
Neutralization assay
Supernatant containing pseudotyped particles were pre-
incubated for 1 h at 37 jC with four serial human-
neutralizing sera or one nonneutralizing human serum
(Burrer et al., 2001) before infection of GHOST-CCR5
cells in triplicate wells in 96-well plates. The volume of
supernatant loaded in each well corresponded to the quan-
tity of pseudotyped particles necessary to promote 80000–
100000 relative light units (RLU) after infection of per-
missive cells. After an overnight incubation, the medium
was replaced and incubation took place during additional 2
days. After cell lysis, the infectivity was measured by using
LucLite Plus kit (Perkin–Elmer) and luminescence was
read on a TopCount apparatus (Packard Biosciences).
Neutralizing titers were expressed as the reciprocal of the
plasma dilution required to protect 50% of cells from
pseudoviruses infection.
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